WATCHMAN FLX Pro European Registry
← catalyst calendarNCT07262255 · readout ≤ 376 d
Sponsored by Boston Scientific Corporation (industry) · BSX — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
1,000estimated
Sites
19
Countries
Denmark, Germany, Italy +3
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-17 | actual | When the study began enrolling |
| Primary completion | Aug 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Sep 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-13 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Non-valvular Atrial Fibrillation (AF)
- Left Atrial Appendage Closure
Intervention
- Device: Left atrial appendage closure
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with a safety event treated with the WATCHMAN FLX Pro
measured Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
Number of participants with a safety event treated with the VersaCross Connect™ LAAC Access Solution
measured Between the time of procedure and within 7 days following the procedure or by hospital discharge, whichever is later
Number of participants with a successful VersaCross Connect™ LAAC Access Solution treatment
measured Completion of transseptal puncture
Permalink · BSX's whole pipeline · Catalyst calendar · Every registered study · What changed